Please login to the form below

Not currently logged in
Email:
Password:

Amgen to buy BioVex

Amgen has said it is to acquire the US-based biotech BioVex in a deal potentially worth up to $1bn

Amgen has said it is to acquire the US-based biotech BioVex in a deal potentially worth up to $1bn.

Global therapeutic research and manufacturing firm, Amgen, is to pay $425m upfront with an additional $575m available to BioVex if certain research and sales milestones are met.

The boards of directors for both companies have approved the deal, which is expected to close by the end of the first quarter of 2011. The transaction will see BioVex become a wholly owned subsidiary of Amgen.

BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer.

Clinical studies have seen positive results for the vaccine, with BioVex currently enrolling patients for phase III trials.

The trials will continue after the takeover, as confirmed by Roger M Perlmutter, executive vice president, R&D, Amgen: "Amgen is particularly excited about joining with BioVex and its talented staff to focus on advancing this late-stage investigational therapy, with the hope of bringing it to market within the next few years."

Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX in multiple solid tumour indications given their impressive oncology franchise and expertise in biologics manufacturing and development."

25th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics